CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals (Nasdaq: IDRA) today announced that Nicola La Monica, Ph.D., Vice President of Biology at Idera, will present at the Cancer Immunotherapy Summit on February 28, 2012, at 2:30 pm ET in Boston, MA. Dr. La Monica, in an oral presentation entitled “TLR Modulation for Immunotherapy of Cancer”, will provide an overview of Idera’s oncology program using agonists of Toll-like receptors (TLRs). Idera’s TLR agonist candidates modulate receptor-mediated immune responses and are being studied as immune modifiers in the potential therapy of cancer.
